Eflornithine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Eflornithine: From African Trypanosomiasis to Esotropia
One-Sentence Summary
Eflornithine (DFMO, difluoromethylornithine) is an irreversible inhibitor of ornithine decarboxylase (ODC) — the rate-limiting enzyme in polyamine biosynthesis — approved internationally for second-stage African sleeping sickness (T. brucei gambiense) and topical facial hair reduction (Vaniqa). The TxGNN model ranks Esotropia as its #1 predicted new indication with a score of 99.85%; however, the current evidence base contains 0 clinical trials and 0 publications for this direction, suggesting the top prediction is likely a knowledge graph topological artefact. Among all 10 ranked predictions, Monoclonal Gammopathy (rank 8) carries the richest body of supporting preclinical evidence, with 9 publications spanning in vitro cytotoxicity and early clinical pharmacology studies conducted between 1985 and 1995.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | African Trypanosomiasis (T. brucei gambiense) / Facial Hair Reduction |
| Predicted New Indication | Esotropia (TxGNN Rank 1) |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on the mechanistic rationale embedded in the prediction records, Eflornithine (DFMO, α-difluoromethylornithine) acts as an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine biosynthesis. By depleting cellular polyamines (putrescine, spermidine, spermine), DFMO arrests cell proliferation and — in T. brucei gambiense — exploits the parasite’s unusually slow ODC protein turnover, causing lethal polyamine depletion at concentrations tolerated by human cells.
Esotropia (convergent strabismus) is a neuromuscular ophthalmological condition caused by imbalanced extraocular muscle tone or abnormal cranial nerve innervation. No established mechanistic link exists between ODC/polyamine metabolism and esotropia pathophysiology. The high TxGNN score (99.85%) is assessed in the prediction rationale as an indirect topological connection within the knowledge graph — likely routed through shared cell proliferation or neurodevelopmental nodes — and is classified as a probable false positive.
Across all 10 ranked predictions, two candidates carry substantially more meaningful mechanistic rationale than the top-ranked esotropia. Bovine Trypanosomiasis (rank 6) is a direct mechanistic extension of the approved human indication — both T. brucei subspecies depend on ODC-driven polyamine synthesis — though species-specific ODC turnover kinetics in T. b. brucei present a key development barrier. Monoclonal Gammopathy / Multiple Myeloma (rank 8) is supported by peer-reviewed evidence from 1985–1995 documenting ODC gene amplification in human myeloma cells, direct DFMO cytotoxicity in the 8226 cell line, and rearrangement of the ODC gene with the immunoglobulin heavy chain locus — a mechanistic fingerprint unique to this disease.
Clinical Trial Evidence
Currently no related clinical trials registered for Eflornithine in esotropia.
Literature Evidence
Currently no related literature available for Eflornithine in esotropia.
Supplementary: Literature Evidence — Monoclonal Gammopathy (Rank 8)
The following section documents the highest-evidence prediction in this report (rank 8, score 98.18%, evidence level L4). It is provided because the rank 1 indication (esotropia) has no supporting evidence and the monoclonal gammopathy evidence represents the most scientifically actionable finding in this pack.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3141118 | 1988 | Clinical Pharmacology | Chemotherapy | DFMO + MGBG combination administered to patients with refractory leukemia and multiple myeloma; polyamine levels increased in peripheral blood and bone marrow mononuclear cells after first MGBG dose despite DFMO co-administration |
| 3139580 | 1988 | Clinical Observation | Investigational New Drugs | Dose-escalating IV DFMO (5.5–64 g/m²/day) in 9 patients with refractory acute leukemia or multiple myeloma; serial polyamine biomarker measurement supports ODC-pathway engagement as a pharmacodynamic endpoint |
| 3015379 | 1986 | In vitro | Cancer Research | DFMO modulates etoposide (VP-16) cytotoxicity and DNA strand scission in 8226 human myeloma cells via polyamine-mediated alteration of topoisomerase II activity; establishes DFMO as a combination sensitiser in myeloma |
| 3109382 | 1987 | In vitro — Resistance Mechanism | Biochemical Journal | Stepwise DFMO selection of Sultan human IgG-myeloma cells produced ~10-fold ODC gene amplification and proportionally elevated ODC activity; defines gene amplification as the primary acquired resistance mechanism |
| 3107550 | 1987 | In vitro — Resistance Mechanism | Biochemical & Biophysical Research Communications | Alternative DFMO resistance pathway identified in human myeloma cells without ODC overproduction; cells maintain detectable putrescine and spermidine via alternative route, informing combination strategy design |
| 2501085 | 1989 | Molecular Biology | EMBO Journal | Functional ODC gene rearranged in a head-to-head configuration with the γ1 immunoglobulin heavy chain switch region in DFMO-resistant mouse myeloma 653-1 cells — a c-myc–analogous translocation suggesting ODC plays a special oncogenic role in plasma cell malignancy |
| 1898373 | 1991 | Molecular Biology | Biochemical Journal | PCR/RT quantification of ODC gene dosage, hnRNA, and mature mRNA in parental and DFMO-resistant human Sultan myeloma cells; characterises transcriptional and post-transcriptional regulation of resistance |
| 7646459 | 1995 | In vitro | Biochemical Journal | 10-month follow-up of Sultan cells after DFMO withdrawal; tracks ODC gene copy number, methylation, mRNA, protein, activity, and polyamine levels — demonstrates slow de-amplification kinetics with clinical relevance for treatment holiday design |
| 3934157 | 1985 | Basic Science — Molecular | Journal of Biological Chemistry | ODC in DFMO-resistant mouse myeloma cells is regulated translationally by polyamines; describes feedback loop underpinning DFMO resistance via ODC gene amplification — foundational mechanistic reference |
India Market Information
Eflornithine currently has no registered products in India. The drug is not marketed in this jurisdiction, and no license data is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold (for Esotropia — Rank 1 TxGNN Prediction)
Rationale: The top-ranked TxGNN prediction (esotropia, score 99.85%) is assessed as a probable knowledge graph topological false positive. No mechanistic bridge links ODC/polyamine metabolism to extraocular muscle innervation disorders, and the evidence package contains zero clinical trials and zero publications supporting this indication. Under current evidence, forward investment is not justified.
To Proceed with Esotropia, the Following is Needed:
- A credible mechanistic hypothesis connecting polyamine depletion to ocular motor neuron or extraocular muscle physiology
- At least one preclinical study (animal model or cell assay) demonstrating a DFMO effect relevant to strabismus
- Expert consultation from a neuro-ophthalmologist
Priority Redirect — Higher-Value Indications Identified in This Pack:
| Rank | Disease | Evidence Level | Recommendation | Priority Next Step |
|---|---|---|---|---|
| 6 | Bovine Trypanosomiasis | L4 | Research Question | Veterinary PK/PD study comparing ODC turnover in T. b. brucei vs T. b. gambiense; assess whether DFMO dosing can overcome faster ODC replenishment |
| 8 | Monoclonal Gammopathy | L4 | Research Question | Systematic literature review (1985–2026); modern in vitro validation in current myeloma cell lines; design DFMO combination strategy with bortezomib or IMiDs |
To Advance the Monoclonal Gammopathy Indication, the Following is Needed:
- Systematic review covering all DFMO studies in plasma cell dyscrasias published from 1985 to present
- Modern in vitro validation using representative myeloma lines (e.g., MM.1S, RPMI 8226, U266) with quantification of ODC copy number as a stratification biomarker
- Assessment of DFMO combination synergy with current standard-of-care agents (bortezomib, lenalidomide, daratumumab)
- Complete MOA documentation and package insert safety data — both are currently missing (Data Gaps DG001 and DG002) and are required before any clinical translation step
⚠️ This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.